Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) Releases Earnings Results

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) issued its quarterly earnings results on Thursday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. The company had revenue of $0.78 million during the quarter.

Inspira Technologies OXY B.H.N. Stock Down 1.3%

QTEX traded down $0.01 during midday trading on Thursday, hitting $0.76. The stock had a trading volume of 2,162,777 shares, compared to its average volume of 10,952,462. Inspira Technologies OXY B.H.N. has a 1 year low of $0.28 and a 1 year high of $3.85. The company’s fifty day moving average is $0.93. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.56 and a quick ratio of 1.30.

Inspira Technologies OXY B.H.N. announced that its board has authorized a share buyback plan on Monday, June 22nd that permits the company to buyback 2,000,000,000,000 outstanding shares. This buyback authorization permits the company to reacquire up to 5.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research note on Monday, August 24th. Wall Street Zen cut shares of Inspira Technologies OXY B.H.N. from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies OXY B.H.N. Ltd. is an Israeli medical technology company focused on developing advanced respiratory-support systems for patients experiencing acute respiratory failure. The company’s technology is intended to support blood oxygenation and carbon-dioxide removal while potentially reducing reliance on invasive mechanical ventilation.

Its principal product platform is the INSPIRA ART system, an extracorporeal respiratory-support technology designed to oxygenate blood outside the body and return it to the patient.